CD19 and B-cell acute lymphoblastic leukemia: At present, blinatumomab, a CD19 × CD3 antibody-based bispecific molecule, is the only example of an immune cell-engaging bispecific drug that has FDA approval for the treatment of disease—B cell acute lymphoblastic leukemia (69, 70).